ARTRYA LIMITED (AYA)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AYA

AYA - ARTRYA LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.03
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.07

02 Sep
2025

0.030

OPEN

$2.09

1.47%

HIGH

$2.12

421,362

LOW

$2.01

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-17.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx18.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-14.0 M
Net Profit Margin xxxxxxxxxxxxxxx-58,592.86 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-86.14 %
Return on Invested Capital xxxxxxxxxxxxxxx-84.15 %
Return on Assets xxxxxxxxxxxxxxx-76.86 %
Return on Equity xxxxxxxxxxxxxxx-86.14 %
Return on Total Capital xxxxxxxxxxxxxxx-111.34 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-14.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxxxxx3.83

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.3 M
Capex % of Sales xxxxxxxxxxxxxxx939.29 %
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx21 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

01/09/2025

1

Buy

$3.51

69.57%

Petra Capital highlights the FDA clearance of Artrya's Salix Coronary Plaque (SCP) transforms its risk profile, enabling a high-value fee-per-scan model. It paves the way to profitability in FY27 and over $120m revenue by FY29 on the broker's assessment.

The broker expects SCP to drive over 70% of the company's forecast revenues.

FY25 net loss of -$16.4m was in line with the broker's forecast. FY26 EPS forecast unchanged, FY27 lowered by -16% on higher opex but FY28 upgraded by 12%.

Buy. Target rises to $3.51 from $2.87.

FORECAST
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -10.10 cents.
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of 3.40 cents.

AYA STOCK CHART